1. Home
  2. RVPH vs FBIO Comparison

RVPH vs FBIO Comparison

Compare RVPH & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • FBIO
  • Stock Information
  • Founded
  • RVPH 2006
  • FBIO 2006
  • Country
  • RVPH United States
  • FBIO United States
  • Employees
  • RVPH N/A
  • FBIO N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • FBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVPH Health Care
  • FBIO Health Care
  • Exchange
  • RVPH Nasdaq
  • FBIO Nasdaq
  • Market Cap
  • RVPH 37.1M
  • FBIO 48.2M
  • IPO Year
  • RVPH N/A
  • FBIO N/A
  • Fundamental
  • Price
  • RVPH $1.45
  • FBIO $1.81
  • Analyst Decision
  • RVPH Strong Buy
  • FBIO Strong Buy
  • Analyst Count
  • RVPH 5
  • FBIO 4
  • Target Price
  • RVPH $14.50
  • FBIO $16.33
  • AVG Volume (30 Days)
  • RVPH 264.7K
  • FBIO 629.5K
  • Earning Date
  • RVPH 11-12-2024
  • FBIO 11-12-2024
  • Dividend Yield
  • RVPH N/A
  • FBIO N/A
  • EPS Growth
  • RVPH N/A
  • FBIO N/A
  • EPS
  • RVPH N/A
  • FBIO N/A
  • Revenue
  • RVPH N/A
  • FBIO $82,624,000.00
  • Revenue This Year
  • RVPH N/A
  • FBIO N/A
  • Revenue Next Year
  • RVPH N/A
  • FBIO $81.63
  • P/E Ratio
  • RVPH N/A
  • FBIO N/A
  • Revenue Growth
  • RVPH N/A
  • FBIO 31.68
  • 52 Week Low
  • RVPH $0.60
  • FBIO $1.24
  • 52 Week High
  • RVPH $6.80
  • FBIO $4.43
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 62.27
  • FBIO 61.24
  • Support Level
  • RVPH $1.15
  • FBIO $1.50
  • Resistance Level
  • RVPH $1.54
  • FBIO $1.65
  • Average True Range (ATR)
  • RVPH 0.11
  • FBIO 0.09
  • MACD
  • RVPH 0.02
  • FBIO 0.05
  • Stochastic Oscillator
  • RVPH 82.00
  • FBIO 91.49

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About FBIO Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Share on Social Networks: